Authors


Vitaly Margulis, MD

Latest:

Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC

Vitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial.


Hesham A. Yasin, MD

Latest:

BCG-unresponsive NMIBC: Current evidence and options

Multiple investigational agents have been developed and are being studied.


Scott MacDiarmid, MD, FRCPSC

Latest:

Future of Overactive Bladder Treatment

Drs MacDiarmid and Rogers discuss barriers to OAB treatments and therapies on the horizon.


Scott B. Sellinger, MD

Latest:

Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.


Phillip M. Pierorazio, MD

Latest:

Urologist discusses when to say “no” as a professional

"Saying 'no' is one of our biggest challenges in our careers as physicians," according to Phillip M. Pierorazio, MD.


Justin Wright, MA, MBA

Latest:

A primer on DNA sequencing for the practicing urologist

Embracing and understanding new and emerging molecular techniques will improve patient outcomes.


Ernest A. Morton, MD, MBA, MS

Latest:

Ernest Morton, MD, shares initial findings on the use of an AI scribe

“Physicians are spending, depending on how much they utilize it, 20% to 30% less time on nights and weekends,” says Ernest A. Morton, MD, MBA, MS.


Meade Monger

Latest:

Reining in the administrative burden in health care

Doctors and medical practices are mired in administrative tasks.


Richard Payerchin

Latest:

Congress to again consider prior authorization reform legislation

The bill has a mass of legislative supporters – at least 41 senators and 127 representatives, along with more than 370 organizations representing patients, physicians, hospitals and Medicare Advantage plans.


Darren R. Feldman, MD

Latest:

Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC

The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.


Philip Abbosh, MD, PhD

Latest:

3D bioprinting technology facilitates development of an in vitro biomimetic bladder model

"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.


R. Jonathan Henderson, MD

Latest:

Final Thoughts and Clinical Trials in NMIBC

Experts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).


Jeremie Calais, MD, PhD

Latest:

Jeremie Calais, MD, on development of a prostate cancer imaging reporting template

“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.


Nima Almassi, MD

Latest:

iRARC adoption is slow but persistent in bladder cancer

"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.


Denise Myshko

Latest:

Post-surgery nivolumab boosts disease-free survival in muscle-invasive urothelial carcinoma

Adjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.


Samuel Haywood, MD

Latest:

Race-based adjustment of eGFR: Current opinions and impact on urologic oncology

“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.


Conor Killmurray

Latest:

Talazoparib/enzalutamide significantly boosts OS in mCRPC

"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.



William Meeks

Latest:

Is there a difference between MD and DO in urology?

"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.


Mohit Khera, MD, MBA, MPH

Latest:

Mohit Khera, MD, on the impact of penile prosthesis implant on mental health

“What [we] found was that those men who received a penile implant had a significant reduction in depression and psychological distress," says Mohit Khera, MD, MBA, MPH.


Alexandra Rogers, MD

Latest:

Reimplantation of Tibial Nerve Stimulation Device (eCoin)

OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).


Jeff Hall

Latest:

18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer

“Treatment based on visualization of 18F-flotufolastat–avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” said Przemyslaw Twardowski, MD.


Gina M. Badalato, MD

Latest:

Is there a difference between MD and DO in urology?

"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.


Christopher Pieczonka, MD

Latest:

Future Directions in mCRPC

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.


Nele Jessel, MD

Latest:

Physician highlights AI’s potential to improve practice efficiency and alleviate burnout

Artificial intelligence can help curate, decipher, and contextualize the enormous and growing amount of digital data that now comprises a patient’s electronic health record, writes Nele Jessel, MD.


Julie Khazan, CFP

Latest:

How the SECURE Act affects inherited IRAs

Legislation sets 10-year withdrawal window for nonspouse beneficiaries.


Kshitij Pandit, MBBS

Latest:

The evolving role of microRNAs in testicular cancer management

"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.


Thomas E. Hutson, DO, PharmD

Latest:

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.


Jason M. Broderick

Latest:

FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUI

The SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.


Cleveland Clinic

Latest:

Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients

Glean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year

© 2025 MJH Life Sciences

All rights reserved.